Multicenter, Observational Study of Lanreotide Depot for Treatment of Patients with Acromegaly in the United States
Latest Information Update: 20 Apr 2017
At a glance
- Drugs Lanreotide (Primary)
- Indications Acromegaly
- Focus Adverse reactions; Therapeutic Use
- Acronyms SODA
- Sponsors Ipsen
- 04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society
- 04 Apr 2016 Interim results assessing extended dosing interval (n = 241) presented at The 98th Annual Meeting of the Endocrine Society.
- 24 Aug 2015 New trial record